AAAAAA

   
Results: 1-18 |
Results: 18
HISTOLOGIC-FINDINGS IN PROLONGED ANDROGEN DEPRIVATION PRIOR TO PROSTATECTOMY
Authors: CIVANTOS F PINTO E SOLOWAY M
Citation: F. Civantos et al., HISTOLOGIC-FINDINGS IN PROLONGED ANDROGEN DEPRIVATION PRIOR TO PROSTATECTOMY, Modern pathology, 11(1), 1998, pp. 79-79
CASODEX(TM) 10-200 MG DAILY, USED AS MONOTHERAPY FOR THE TREATMENT OFPATIENTS WITH ADVANCED PROSTATE-CANCER - AN OVERVIEW OF THE EFFICACY,TOLERABILITY AND PHARMACOKINETICS FROM 3-PHASE-II DOSE-RANGING STUDIES
Authors: TYRRELL CJ DENIS L NEWLING D SOLOWAY M CHANNER K COCKSHOTT ID
Citation: Cj. Tyrrell et al., CASODEX(TM) 10-200 MG DAILY, USED AS MONOTHERAPY FOR THE TREATMENT OFPATIENTS WITH ADVANCED PROSTATE-CANCER - AN OVERVIEW OF THE EFFICACY,TOLERABILITY AND PHARMACOKINETICS FROM 3-PHASE-II DOSE-RANGING STUDIES, European urology, 33(1), 1998, pp. 39-53
OBSERVATIONS ON THE NATURAL-HISTORY OF BPH IN MEN FOLLOWED IN A 4-YEAR PLACEBO-CONTROLLED TRIAL
Authors: HOLTGREWE L BRUSKEWITZ R GLICKMAN S PETERSON L TENOVER L ERCOLE C SUSSMAN DO AUERBACH S SOLOWAY M JOHNSON E WANG D PAPPAS F
Citation: L. Holtgrewe et al., OBSERVATIONS ON THE NATURAL-HISTORY OF BPH IN MEN FOLLOWED IN A 4-YEAR PLACEBO-CONTROLLED TRIAL, The Journal of urology, 159(5), 1998, pp. 396-396
MULTICENTER EFFICACY AND SAFETY STUDY OF INTRAVESICAL AD-32 (VALRUBICIN) IN THE TREATMENT OF PATIENTS WITH REFRACTORY BLADDER-CARCINOMA IN-SITU
Authors: BAHNSON R BROSMAN S GREENBERG R BROWN BT DALKIN B MIDDLETON R SOLOWAY M STEINBERG G WAJSMAN Z
Citation: R. Bahnson et al., MULTICENTER EFFICACY AND SAFETY STUDY OF INTRAVESICAL AD-32 (VALRUBICIN) IN THE TREATMENT OF PATIENTS WITH REFRACTORY BLADDER-CARCINOMA IN-SITU, The Journal of urology, 159(5), 1998, pp. 551-551
HA-HASE TEST - A TEST FOR DETECTING BLADDER-CANCER AND MONITORING TUMOR RECURRENCE
Authors: LOKESHWAR V YOUNG M WEI D BRADY J SOLOWAY M BLOCK N
Citation: V. Lokeshwar et al., HA-HASE TEST - A TEST FOR DETECTING BLADDER-CANCER AND MONITORING TUMOR RECURRENCE, The Journal of urology, 159(5), 1998, pp. 923-923
ASSESSMENT OF END-POINTS FOR CLINICAL-TRIALS FOR LOCALIZED PROSTATE-CANCER
Authors: SCHELLHAMMER P COCKETT A BOCCONGIBOD L GOSPODAROWICZ M KRONGRAD A THOMPSON IM SCARDINO P SOLOWAY M ADOLFSSON J
Citation: P. Schellhammer et al., ASSESSMENT OF END-POINTS FOR CLINICAL-TRIALS FOR LOCALIZED PROSTATE-CANCER, Urology, 49(4A), 1997, pp. 27-38
PSA LEVELS AND THE RATE OF POSITIVE SURGICAL MARGINS IN RADICAL PROSTATECTOMY SPECIMENS PRECEDED BY ANDROGEN BLOCKADE IN CLINICAL B-2 (T2BNXMO) PROSTATE-CANCER
Authors: MCLEOD DG JOHNSON CF KLEIN E PEABODY JO COFFIELD S SOLOWAY M
Citation: Dg. Mcleod et al., PSA LEVELS AND THE RATE OF POSITIVE SURGICAL MARGINS IN RADICAL PROSTATECTOMY SPECIMENS PRECEDED BY ANDROGEN BLOCKADE IN CLINICAL B-2 (T2BNXMO) PROSTATE-CANCER, Urology, 49(3A), 1997, pp. 70-73
MARGINS IN RADICAL PROSTATECTOMIES - IMPACT ON PROGNOSIS
Authors: CIVANTOS F WATSON R PINTO JE SOLOWAY M
Citation: F. Civantos et al., MARGINS IN RADICAL PROSTATECTOMIES - IMPACT ON PROGNOSIS, Laboratory investigation, 76(1), 1997, pp. 410-410
INCIDENTAL PROSTATIC ADENOCARCINOMA IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER-CANCER
Authors: ABBAS A HOCHBERG D CIVANTOS F SOLOWAY M
Citation: A. Abbas et al., INCIDENTAL PROSTATIC ADENOCARCINOMA IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER-CANCER, European urology, 30(3), 1996, pp. 322-326
CLINICAL-TRIALS OF BICALUTAMIDE AS MONOTHERAPY FOR PROSTATE-CANCER - DISCUSSION
Authors: ANDRIOLE GL DENIS L BLACKLEDGE G SCHMIDT J SAGALOWSKY A IVERSEN P SOLOWAY M FURR B BLOCK N BANERJEE T YOUNG J KOLVENBAG GCM OESTERLING JE NIEH PTC MONTIE JE SCHELLHAMMER PF BALES GT KLEIN EA BROSMAN S
Citation: Gl. Andriole et al., CLINICAL-TRIALS OF BICALUTAMIDE AS MONOTHERAPY FOR PROSTATE-CANCER - DISCUSSION, Urology, 47(1A), 1996, pp. 48-53
MAXIMAL ANDROGEN BLOCKADE FOR PATIENTS WITH METASTATIC PROSTATE-CANCER - OUTCOME OF A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONEANALOGUE THERAPY
Authors: SCHELLHAMMER P SHARIFI R BLOCK N SOLOWAY M VENNER P PATTERSON AL SAROSDY M VOGELZANG N JONES J KOLVENBAG G
Citation: P. Schellhammer et al., MAXIMAL ANDROGEN BLOCKADE FOR PATIENTS WITH METASTATIC PROSTATE-CANCER - OUTCOME OF A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONEANALOGUE THERAPY, Urology, 47(1A), 1996, pp. 54-60
CLINICAL-DATA ON THE ROLE OF BICALUTAMIDE IN METASTATIC PROSTATE-CANCER - DISCUSSION
Authors: RICHIE JP SCHELLHAMMER PF SCHER H HAAS G PATTERSON K SAGALOWSKY A KOLVENBAG GJCM KENNEALEY G IVERSEN P BROSMAN S KLEIN EA FURR B BLOCK N DENIS L SCHMIDT J SOLOWAY M OESTERLING JE YOUNG J
Citation: Jp. Richie et al., CLINICAL-DATA ON THE ROLE OF BICALUTAMIDE IN METASTATIC PROSTATE-CANCER - DISCUSSION, Urology, 47(1A), 1996, pp. 80-84
THE EXPECTED VALUE OF BICALUTAMIDE IN THE MANAGEMENT OF PROSTATIC DISEASE - DISCUSSION
Authors: OESTERLING JE MCLEOD DG RICHIE JP MALKOWICZ SB ANDRIOLE GL SEIDMON J KOLVENBAG GJCM BLACKLEDGE G SCHMIDT J KLEIN EA SOLOWAY M MONTIE JE GOMELLA L HAAS G SCHER H RAMSEY EW BROSMAN S LYNCH D WAJSMAN Z BABAIAN R ROMAS N BLOCK N
Citation: Je. Oesterling et al., THE EXPECTED VALUE OF BICALUTAMIDE IN THE MANAGEMENT OF PROSTATIC DISEASE - DISCUSSION, Urology, 47(1A), 1996, pp. 90-96
FINASTERIDE (PROSCAR) EFFECT IN PROSTATIC-CARCINOMA
Authors: CIVANTOS F SOLOWAY M
Citation: F. Civantos et M. Soloway, FINASTERIDE (PROSCAR) EFFECT IN PROSTATIC-CARCINOMA, Laboratory investigation, 74(1), 1996, pp. 405-405
A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG THERAPY, IN PATIENTS WITH ADVANCED PROSTATE-CANCER
Authors: SCHELLHAMMER P SHARIFI R BLOCK N SOLOWAY M VENNER P PATTERSON AL SAROSDY M VOGELZANG N JONES J KOLVENBAG G
Citation: P. Schellhammer et al., A CONTROLLED TRIAL OF BICALUTAMIDE VERSUS FLUTAMIDE, EACH IN COMBINATION WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG THERAPY, IN PATIENTS WITH ADVANCED PROSTATE-CANCER, Urology, 45(5), 1995, pp. 745-752
TREATMENT WITH FINASTERIDE FOLLOWING RADICAL PROSTATECTOMY FOR PROSTATE-CANCER
Authors: ANDRIOLE G LIEBER M SMITH J SOLOWAY M SCHROEDER F KADMON D DEKERNION J RAJFER J BOAKE R CRAWFORD D RAMSEY E PERREAULT J TRACHTENBERG J FRADET T BLOCK N MIDDLETON R NG J FERGUSON D GORMLEY G
Citation: G. Andriole et al., TREATMENT WITH FINASTERIDE FOLLOWING RADICAL PROSTATECTOMY FOR PROSTATE-CANCER, Urology, 45(3), 1995, pp. 491-497
ANDROGEN DEPRIVATION EFFECT IN PROSTATIC-CARCINOMA - A MULTICENTER STUDY
Authors: CIVANTOS F MARCIAL M BANKS E HO CK SPEIGHTS VO DREW P MURPHY WM SOLOWAY M
Citation: F. Civantos et al., ANDROGEN DEPRIVATION EFFECT IN PROSTATIC-CARCINOMA - A MULTICENTER STUDY, Laboratory investigation, 72(1), 1995, pp. 74-74
INFLAMMATION AND NECROSIS IN PROSTATIC-CARCINOMA FOLLOWING PRESURGICAL LUPROLIDE AND FLUTAMIDE ANDROGEN INHIBITION
Authors: CIVANTOS F SOLOWAY M
Citation: F. Civantos et M. Soloway, INFLAMMATION AND NECROSIS IN PROSTATIC-CARCINOMA FOLLOWING PRESURGICAL LUPROLIDE AND FLUTAMIDE ANDROGEN INHIBITION, Laboratory investigation, 70(1), 1994, pp. 10000072-10000072
Risultati: 1-18 |